Follow The Filings

KTTA Pasithea Therapeutics Corporation

Health Care, filed as PASITHEA THERAPEUTICS CORP (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.1%
  • $1.1M
  • 1 new

In 2026 Q2 James Silverman opened a position in Pasithea Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 0.1% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman New 0.10%

Who owns KTTA

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 0.10% New 0.10% 2,050,000 $1.1M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by KTTA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All KTTA insider trades
  • $203K bought by 4 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Coastlands Capital LP 10% owner
    Buy
    $53K 100,000 shares at $0.5300 +2.7% to stake
    Traded Jun 17 Filed Jun 22
    ↗
  2. Lawrence Steinman Director
    Buy
    $100K 133,333 shares at $0.7500 +201% to stake
    Traded Nov 28, 2025 Filed Dec 1, 2025
    ↗
  3. Tiago Marques CEO
    Buy
    $25K 33,333 shares at $0.7500 +83% to stake
    Traded Nov 28, 2025 Filed Dec 1, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 2 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 8.01 Filing Doc
8-K 5.07,9.01 Filing Doc
8-K 3.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q QUARTERLY REPORT Filing Doc
DEF 14A DEFINITIVE PROXY STATEMENT Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q QUARTERLY REPORT Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
10-K ANNUAL REPORT Filing Doc
SCHEDULE 13G — Filing Doc
8-K 3.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.02,5.03,5.07,9.01 Filing Doc
DEF 14A DEFINITIVE PROXY STATEMENT Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated 10 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$15.96M -$13.9M -$20.43M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $16.69M $7.37M $56.46M
Total non-current assets * $9.42M $8.7M $3.78M
Total assets $26.12M $16.06M $60.24M
Total current liabilities $2.63M $1.12M $4.97M
Total non-current liabilities $84,366 $162,172 $46,871
Total equity $23.4M $14.78M $55.22M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations — — -$15.21M
Cash from investing — — $11,000
Cash from financing — — $63.52M
Net change in cash -$16.76M -$9.41M $48.34M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Q2 2026

Period archive